Interim report January - September 2010

  * The Group's sales for the period amounted to SEK 412 (481) million.
  * EBITDA amounted to SEK -37* (75) million.
  * Operating profit totalled SEK -129** (58) million.
  * The net profit after tax for the period amounted to SEK -163*** (16)
    million.
  * Earnings per share after tax for the period were SEK -0.48 (0.05) before
  * and after dilution.

 Significant events during the period
  * Niklas Prager was elected as the new Chairman of the Board of BioPhausia.
  * BioPhausia became the main supplier of parallel-imported pharmaceuticals to
    Apoteksgruppen.
  * Maris Hartmanis took up the position of BioPhausia CEO on 9 August.
  * The Board decided to streamline operations and focus on the Nordic region.
  * BioPhausia sold OTC products to Meda AB for SEK 190 million, which resulted
    in a capital loss of SEK 74 mkr.
  * Impairment losses of SEK 76 million were recognised for intangible assets
    and SEK 17 million for inventories.
  * Bank loan repayments totalled SEK 245 million during the period.


Period July - September
  * The Group's sales for the period amounted to SEK 147 (148) million.
  * EBITDA amounted to SEK -64* (21) million.
  * Operating profit totalled SEK -120** (15) million.
  * The net profit after tax for the period amounted to SEK -125*** (1) million.
  * Earnings per share after tax for the period were SEK -0.36 (0.00 ) before
    and after dilution.


*Includes non-recurring costs totalling SEK 99 million for the period and SEK
88 million for the quarter. For more information, see Note 7.
**Includes non-recurring costs totalling SEK 175 million for the period and SEK
140 million for the quarter. For more information, see Note 7.
***Includes non-recurring costs totalling SEK 186 million for the period and SEK
151 million for the quarter. For more information, see Note 7.


[HUG#1461598]